We Speak Methadone (and buprenorphine)

A NAMA Recovery Forum for Medication Assisted Treatment patients, family and advocates. (Issues or Questions about registration and/or the forum? Email zac@tnmethadone.org OR sapphirematthews@gmail.com)
It is currently Mon Nov 20, 2017 2:23 am

All times are UTC - 5 hours


Forum rules


Please click here to view the forum rules



Post new topic Reply to topic  [ 1 post ] 
Author Message
 Post subject: FDA Approves Bunavail for Opioid Addiction
PostPosted: Tue Jun 10, 2014 9:27 pm 
Offline
Administrator
User avatar

Joined: Sun May 04, 2014 9:54 pm
Posts: 196
Location: North Georgia
FDA Approves Bunavail for Opioid Addiction
Caroline Cassels
June 10, 2014

The US Food and Drug Administration (FDA) has approved a new drug for the maintenance treatment of opioid dependence.

BioDelivery Sciences International Inc announced in a release that it has received FDA approval of Bunavail (buprenorphine and naloxone) buccal film (CIII) and expects to launch the drug late in the third quarter of 2014.

According to the manufacturer, the drug has a unique adhesive "inside the cheek" delivery system that improves absorption and plasma concentrations of buprenorphine and therefore can be delivered at a lower dose, which may help reduce the potential for misuse and diversion and lessen the incidence of side effects.

The company asserts that unlike sublingual products that need to be kept in place under the tongue until they dissolve, the inside-the-cheek film allows patients to talk, swallow, and go about normal daily activities while the medication is being consistently absorbed.

"Bunavail is a novel treatment approach for the more than 2 million people in the US afflicted with opioid dependence," Gregory Sullivan, MD, principal investigator of the phase 3 Bunavail safety study and an addiction specialist and medical director of Parkway Medical Center in Birmingham, Alabama, said in a release.

"Bunavail utilizes advanced drug delivery technology to fulfill an important need for treatment options with improved drug absorption and patient convenience, and as such, may help to address some of the challenges associated with sublingual administration and possibly help improve treatment compliance," Dr. Sullivan added.

SOURCE: http://www.medscape.com/viewarticle/826473?src=wnl_edit_tpal&uac=211814HT

_________________
Zac Talbott, CMA
Email | zac@tnmethadone.org

Chief Operating Officer | Counseling Solutions Treatment Centers
Comprehensive Opioid Treatment Programs
Program Director | Counseling Solutions Treatment Centers - Chatsworth


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC - 5 hours


Who is online

Users browsing this forum: No registered users and 1 guest


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
cron
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group